Clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Haemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), Varicella, pneumococcal conjugate (PCV13), Geriatric Flu, and hepatitis A/hepatitis B (HepA–HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI (0.32, 0.64), p-value: 6.9e−05). Overall, this study identifies existing approved vaccines which can be promising candidates for pre-clinical research and Randomized Clinical Trials towards combating COVID-19.

临床研究正在进行中，以评估现有疫苗是否可以通过训练有素的免疫力来提供针对 SARS-CoV-2 感染的保护。在这项探索性研究中，我们分析了 137,037 名接受过 SARS-CoV-2 PCR 检测的人的免疫记录。我们发现过去接种过脊髓灰质炎、B 型流感嗜血杆菌 (HIB)、麻疹-腮腺炎-风疹 (MMR)、水痘、肺炎球菌结合物 (PCV13)、老年流感和甲型肝炎/乙型肝炎 (HepA-HepB) 疫苗即使在调整了 SARS-CoV-2 地理发病率和检测率、人口统计、合并症和其他疫苗接种数量后，1 年、2 年和 5 年与 SARS-CoV-2 感染率下降相关。此外，年龄、种族/族裔和血型分层分析显示，接种 PCV13 疫苗的黑人中 SARS-CoV-2 发病率显着降低，5 年时间范围内的相对风险为 0.45（n：653，95%） CI (0.32, 0.64)，p 值：6.9e−05)。总体而言，这项研究确定了现有已批准的疫苗，这些疫苗可能成为对抗 COVID-19 的临床前研究和随机临床试验的有希望的候选疫苗。